Pirfenidone use in fibrotic diseases: What do we know so far?

Aldo Torre Martínez-Sánchez Froylan David Sofía Mercedes Narvaez-Chávez Mariana Ariel Herrera-Islas Carlos Alberto Aguilar-Salinas Jacqueline Cordova-Gallardo

Published in: Immunity, inflammation and disease (2024)

Given the increasing incidence of chronic fibrotic conditions, pirfenidone emerges as a potential therapeutic option for these patients. However, further clinical trials are necessary to confirm its therapeutic efficacy in various fibrotic diseases. This review aims to highlight the current evidence of pirfenidone's effects in multiple fibrotic conditions.

Keyphrases

idiopathic pulmonary fibrosis
clinical trial
systemic sclerosis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
pulmonary fibrosis
randomized controlled trial
patient reported outcomes
patient reported
study protocol
drug induced
phase iii